IP Library Granted Patent US 9,012,477
Granted Patent B2
US 9,012,477 · App. 12/652,502 · Granted Apr 21, 2015

Method of treating neuropathic pain

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,012,477
App. No.
12/652,502
Granted
Apr 21, 2015
Kind
B2
Abstract

A method for treating subjects experiencing neuropathic pain is provided. The method involves the application of a solid-forming local anesthetic formulation to a skin surface of the subject experiencing the neuropathic pain and then maintaining the formulation on the skin surface for a period of time sufficient to allow itself to transdermally deliver the local anesthetic to the subject thereby providing relief from the neuropathic pain within about 45 minutes.

Claims (22)

1. A method of treating neuropathic pain in a subject, comprising:

applying a layer of a solid-forming local anesthetic formulation to a skin surface of a human experiencing neuropathic pain, said solid-forming local anesthetic formulation comprising a local anesthetic agent, water, and at least one polymer selected from the group consisting of polyvinyl alcohol, polyvinylpyrrolidone, ethylcellulose, or combinations thereof, and being in the state of a semi-solid before being applied to said skin surface; and

maintaining said layer of said formulation on said skin surface for a period of time sufficient to allow said layer of said formulation to transdermally deliver the local anesthetic to the subject and to form a layer of a coherent soft solid after a sufficient amount of water is evaporated from said layer of said formulation,

wherein the solid-forming local anesthetic formulation is formulated to deliver the local anesthetic agent to the subject until substantially all of the water present in the formulation has evaporated and delivery of the local anesthetic stops or slows significantly so as to have no therapeutic effect thereafter, and wherein the solid-forming local anesthetic formulation provides relief from said neuropathic pain within about 45 minutes after application to the skin surface.

2. The method of claim 1 , wherein the solid-forming local anesthetic formulation is maintained on the skin surface of the subject for a period of time of about 30 minutes to 2 hours.

3. The method of claim 1 , wherein the skin surface is directly over the neuropathic pain.

4. The method of claim 1 , wherein the method further comprises the step of removing the solid-forming local anesthetic formulation after it forms said layer of coherent soft solid by peeling a coherent soft solid from the skin at from 20 to 120 minutes after application.

5. The method of claim 1 , wherein the solid-forming local anesthetic formulation is applied to said skin surface as a layer with a thickness from 0.1 to 3.0 millimeters.

6. The method of claim 1 , wherein the solid-forming local anesthetic formulation is applied to said skin surface as a layer with a thickness from 0.2 to 1.5 millimeters.

7. The method of claim 1 , wherein said local anesthetic agent includes tetracaine.

8. The method of claim 7 , wherein the tetracaine comprises 6 wt % to 8 wt % of the solid-forming local anesthetic formulation before said formulation is applied to said skin surface.

9. The method of claim 1 , wherein said local anesthetic agent includes lidocaine.

10. The method of claim 9 , wherein the lidocaine comprises 6 wt % to 8 wt % of the solid-forming local anesthetic formulation before said formulation is applied to said skin surface.

11. The method of claim 1 , wherein said local anesthetic agent is a eutectic mixture of lidocaine and tetracaine.

12. The method of claim 1 , wherein the local anesthetic agent is selected from the group consisting of lidocaine, tetracaine, prilocaine, ropivacaine, bupivacaine, and mixtures thereof.

13. The method of claim 1 , wherein the local anesthetic is in base form.

14. The method of claim 1 , wherein the solid-forming local anesthetic formulation is formulated to provide relief from said neuropathic pain within about 30 minutes after application to the skin surface.

15. The method of claim 1 , wherein the solid-forming local anesthetic formulation is formulated to provide pain relief for at least 9 hours after an application time of at least 45 minutes.

16. The method of claim 1 , wherein the solid-forming local anesthetic formulation includes at least about 15 wt % water before being applied to said skin surface.

17. The method of claim 1 , wherein the solid-forming local anesthetic formulation includes at least about 22 wt % water before being applied to said skin surface.

18. The method of claim 1 , wherein the solid-forming local anesthetic formulation includes at least about 50 wt % water before being applied to said skin surface.

19. The method of claim 1 , wherein the polymer includes polyvinyl alcohol.

Assignments (7)
RELEASE OF SECURITY INTEREST Recorded May 17, 2023
From: PALADIN LABS INC.
To: NUVO RESEARCH INC.
Reel/Frame 063695/0543 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 1, 2016
From: NUVO RESEARCH INC.
To: CRESCITA THERAPEUTICS INC.
Reel/Frame 040485/0021 →
RELEASE OF SECURITY INTEREST Recorded Jan 9, 2015
From: PALADIN LABS INC.
To: NUVO RESEARCH INC.
Reel/Frame 034675/0010 →
GENERAL SECURITY AGREEMENT Recorded Aug 20, 2012
From: NUVO RESEARCH INC.
To: PALADIN LABS INC.
Reel/Frame 028816/0225 →
CONFIRMATION OF ASSIGNMENT Recorded Jul 10, 2012
From: NUVO RESEARCH AMERICA, INC.
To: NUVO RESEARCH INC.
Reel/Frame 028535/0690 →
CONFIRMATION OF ASSIGNMENT Recorded Jul 6, 2012
From: ZARS PHARMA, INC.
To: NUVO RESEARCH AMERICA, INC.
Reel/Frame 028509/0561 →
RELEASE OF SECURITY INTEREST Recorded May 13, 2011
From: ZIONS FIRST NATIONAL BANK
To: ZARS PHARMA, INC., FORMERLY KNOWN AS ZARS, INC.
Reel/Frame 026276/0717 →